Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
about
SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancerContemporary Treatment of Metastatic Renal Cell CarcinomaSequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspectiveComparative efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: a systematic review and meta-analysisAxitinib in the treatment of renal cell carcinoma: patient selection and perspectivesCurrent Insights into Long Non-Coding RNAs in Renal Cell CarcinomaBeyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinomaChinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinomaCurrent management and future directions in the treatment of advanced renal cell carcinoma-a latin american perspective: 10 years in reviewProfile of nintedanib in the treatment of solid tumors: the evidence to dateMore than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future HoldsClinical experience with everolimus in the second-line treatment of advanced renal cell carcinomaSubverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancerIndividualising treatment choices in a crowded treatment algorithmClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerEvaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinomaHypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell CarcinomaCabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experienceInfluence of Tyrosine Kinase Inhibitors on Hypertension and Nephrotoxicity in Metastatic Renal Cell Cancer PatientsEfficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter StudyRenal cell cancer: overview of the current therapeutic landscape.Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program.Prognosis of metastatic renal cell carcinoma with first-line interferon-α therapy in the era of molecular-targeted therapy.Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience.Continuing a cancer treatment despite tumor growth may be valuable: sunitinib in renal cell carcinoma as example.Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialCritical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinomaOverall survival of first-line axitinib in metastatic renal cell carcinoma: Japanese subgroup analysis from phase II studyAxitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trialRetrospective analysis of the safety and efficacy of high-dose interleukin-2 after prior tyrosine kinase inhibitor therapy in patients with advanced renal cell carcinoma.First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database ConsortiumA phase I pharmacodynamic trial of sequential sunitinib with bevacizumab in patients with renal cell carcinoma and other advanced solid malignanciesSmall molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.Targeted treatments in advanced renal cell carcinoma: focus on axitinib.Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models
P2860
Q24339492-CF823271-3C30-461F-9E28-9747CAF27724Q26740594-694E3AF7-F1E9-4DBF-8785-2711E88D3637Q26744089-AE151DB0-6728-41AE-AA30-EC24A750D5FCQ26746200-503DBCA4-B719-43FF-88F6-B8DFE50EDEB8Q26751341-28BCAFB0-FD5D-45A1-86B3-878720B319ADQ26752381-A829BE3E-D7D7-4697-B6F5-6E50A539CF6AQ26766240-D69048C0-D869-41AD-9C6A-BF0509921EEEQ26772206-1E1A9863-D80E-4186-81E3-607100D8592CQ26773653-508EB872-81B7-4C88-9F25-CFA78FBAA46EQ26774515-E893A47E-2CA2-408F-BB16-247610A77835Q26775134-8576B0BF-DE72-444B-9230-AC87A088795AQ26781662-3E2B7260-9349-404F-8244-96832976F153Q26783514-B76A42F8-9067-4AAF-AA2C-DCB8CC6682D1Q26852704-D6F40C47-2683-4F57-B17D-B3973807A0FFQ27023669-DD3A7E19-F6CF-4C0A-A128-7D04B607E67AQ27024235-74263D57-4069-4A84-88F3-4FAAFC399432Q27028048-B7975B36-9C88-4614-96B3-C42055061FA7Q28066747-65866B29-70D0-47D7-B603-40BB807DE28DQ28072166-DE518337-86EE-44B0-92BF-F4E75400AA34Q28080163-19CDA4E6-0970-4CA1-9CEC-EB94983045EDQ28547506-4E1ACB95-6624-4AAF-BC63-5CAFBBD5DFB8Q30248354-ED3100E8-21A1-473C-A08B-8D2F2320E8F4Q30249385-78B3B7EF-6E9C-467F-9CFC-71BE908DDEA6Q30399006-B2E08FBE-318D-424A-9682-4C3F7B74C030Q33415481-CB868995-F166-415D-95D5-8954E5BCC91EQ33431578-A5B8E165-64BC-41B7-86D3-9EC09CEB3456Q33434845-85E22274-A0DA-4A67-8EF9-E7FF7346CB8CQ33567889-DDAEA270-3915-40CB-9AA8-B8774B7CDB8BQ33633424-A61CA0D9-47F2-4E7F-8A4E-6EDA96A636C5Q33749070-09FA0C62-D904-4C04-B22A-23AC04E10C39Q33750154-7003D6F9-9406-4A08-8D6B-DE48F9ECBCDAQ33754122-A923E403-F434-4D09-A6E5-EF7F5C6D8CC8Q33823247-A0F631E2-9FCA-4976-BB7A-D2BF5D637DFFQ33997879-A1F7DDEB-9DE1-4FB5-9833-2F70B69FDAEEQ34021843-99F5BF61-7506-4856-BBDC-F53D8F5A3EC7Q34183978-4C6E7EEE-0B33-40CF-A0C9-8A60E9E6FB44Q34356881-32DB24F4-CAA6-4D10-871E-5B6A5E4B983CQ34371248-648EB18F-3B2D-478D-B5B3-1CF9D8AA93CCQ34661185-6E01DD35-D06C-4F7E-8A4E-14E90560D740Q34978329-873709BD-054F-4603-AE28-3894D8DD8ADE
P2860
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Axitinib versus sorafenib as s ...... om a randomised phase 3 trial.
@ast
Axitinib versus sorafenib as s ...... om a randomised phase 3 trial.
@en
Axitinib versus sorafenib as s ...... om a randomised phase 3 trial.
@nl
type
label
Axitinib versus sorafenib as s ...... om a randomised phase 3 trial.
@ast
Axitinib versus sorafenib as s ...... om a randomised phase 3 trial.
@en
Axitinib versus sorafenib as s ...... om a randomised phase 3 trial.
@nl
prefLabel
Axitinib versus sorafenib as s ...... om a randomised phase 3 trial.
@ast
Axitinib versus sorafenib as s ...... om a randomised phase 3 trial.
@en
Axitinib versus sorafenib as s ...... om a randomised phase 3 trial.
@nl
P2093
P1433
P1476
Axitinib versus sorafenib as s ...... om a randomised phase 3 trial.
@en
P2093
Brad Rosbrook
Brian I Rini
Connie Chen
Jamal Tarazi
M Dror Michaelson
Martin E Gore
Piotr Tomczak
Stephane Oudard
Subramanian Hariharan
P304
P356
10.1016/S1470-2045(13)70093-7
P577
2013-04-16T00:00:00Z